CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

Reimbursement challenges in Hungary

László Vécsei, Professor of Neurology and Head of the Neuroscience Research Group, Albert Szent-Györgyi Clinical Center, University of Szeged, Hungary. Three anti-CGRP mAbs are currently approved for use in Hungary, and we have seen excellent responses in some patients, no response in a small number and a very good response in the rest. However, due …

Read more »

Promising real-world experience in South Korea

Byung-Kun Kim, Eulji University School of Medicine, Seoul, South Korea Emgality (galcanezumab) was approved in South Korea in September 2019 and remains the only CGRP therapy available. Between December 2019, when it became available, and July 2020, I prescribed galcanezumab to around 200 patients, 55% of whom had chronic migraine, 40% episodic migraine (high frequency 31%, …

Read more »

CGRP antibody therapies: real-world experience from Australia

Richard J Stark, Alfred Hospital and Monash University, Melbourne, Australia. In Australia we have had the opportunity to treat a limited number of patients with erenumab, galcanezumab and fremanezumab. Each of the companies marketing these agents has produced a scheme enabling subsidised use: patient familiarisation programmes for erenumab and fremanezumab (each limited to 10 patients …

Read more »

Real world prescribing: a view from The Netherlands

Joost Haan, Leiden University Medical Center and the Alrijne Hospital Leiderdorp, The Netherlands. In The Netherlands, erenumab, fremanezumab and galcanezumab are all available to clinicians and, as insurers do not as yet pay for these drugs, all three manufacturers run unmet need programmes through which patients with high frequency migraine can receive free treatment. Erenumab …

Read more »